AL002 *

AL002 is a monoclonal antibody intended to enhance the activity of TREM2.

AL002 is being developed by Alector for the treatment of Alzheimer’s disease and Alector is responsible for the execution of Phase 1 and Phase 2 studies. Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization.

Type of Molecule

Biologic

Target

TREM 2

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Alzheimer's Disease (AD) n/a
Phase 1